Weill Cornell

Accepting patients

DREAMM12

A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degrees of Impaired Renal Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1

Accepting patients

IDP-023

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Learn more
  • Natural Killer Cells (Allogeneic)
  • Phase 1/2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

APG-2575

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Learn more
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

Investigational Cord Blood Units

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

D-ClaPd

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 2

Accepting patients

ISB 1442

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • CD38
  • CD47
  • Phase 1/2
  • Has results

Accepting patients

EZM0414

A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Learn more
  • SET2D Inhibitor
  • Phase 1